Preclinical evaluation of tolvaptan and salsalate combination therapy in a Pkd1-mouse model

Preclinical evaluation of tolvaptan and salsalate combination therapy in a Pkd1-mouse model

Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic disorder and an important cause of end stage renal disease (ESRD). Tolvaptan (a V2R antagonist) is the first disease modifier drug for treatment of ADPKD, but also causes severe polyuria. AMPK activators have...

Full description

Bibliographic Details
Main Authors: Xuewen Song, Wouter N. Leonhard, Anish A. Kanhai, Gregory R. Steinberg, York Pei, Dorien J. M. Peters
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Molecular Biosciences
Subjects:
salsalate
tolvaptan
combination therapy
preclinical trial
gene expression profiling
ADPKD
Online Access:https://www.frontiersin.org/articles/10.3389/fmolb.2023.1058825/full

Similar Items

Similar Items